Safety context
Retatrutide side effects and risks
Retatrutide side effects are still being studied. Phase 2 trial data and ongoing Phase 3 studies can describe observed safety signals, but they do not make retatrutide approved, available, or appropriate for personal use outside a clinical trial.
Key takeaways
- Published trial data are not the same as an FDA-approved label.
- FDA warns about unapproved GLP-1 products, including products sold online as retatrutide.
- Searches about death, cancer, tiredness, alcohol, or side effects should be handled by qualified medical professionals.
- This site does not provide personal risk assessment, dosing, or treatment instructions.
What trial data can tell us
Clinical trials are designed to evaluate benefits and risks under study protocols. A phase 2 obesity trial reported efficacy and safety findings over 48 weeks, and Lilly lists broader Phase 3 studies in progress. Trial findings can inform the research picture, but they do not replace a final regulatory review or product label.
Why online side-effect claims are risky
Searches such as retatrutide death, retatrutide side effects cancer, can retatrutide cause cancer, does retatrutide make you tired, and can you drink on retatrutide often surface forum posts or speculative pages. Those may be worth discussing with a clinician, but they are not a substitute for official trial records, regulator statements, or medical care.
FDA warning context
FDA warns that some unapproved GLP-1 products sold online may be labeled for research use or not for human consumption while being marketed to consumers. FDA says such products may have unknown quality and can be harmful.